Reference
1. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-69, 69a-69k.
2. Menichetti M, Rosso S, Menegatti E, Pazzaglia M. Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report. J Med Case Rep 2015; 9: 274.
3. Rivera-Lebron B, McDaniel M, Ahrar K, Alrifai A, Dudzinski DM, Fanola C, Blais D, Janicke D, Melamed R, Mohrien K, Rozycki E, Ross CB, Klein AJ, Rali P, Teman NR, Yarboro L, Ichinose E, Sharma AM, Bartos JA, Elder M, Keeling B, Palevsky H, Naydenov S, Sen P, Amoroso N, Rodriguez-Lopez JM, Davis GA, Rosovsky R, Rosenfield K, Kabrhel C, Horowitz J, Giri JS, Tapson V, Channick R. Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. Clin Appl Thromb Hemost 2019; 25: 1076029619853037.
4. Yirgin G, Ates I Fau - Katipoglu B, Katipoglu B Fau - Demir BF, Demir Bf Fau - Yilmaz N, Yilmaz N. Pulmonary embolism due to synthetic cannabinoid use: Case report. Turk Kardiyol Dern Ars 2018; 46: 411-13.
5. Pleticha J, Sutton EM. Intraoperative Pulmonary Embolism: A Case Report Emphasizing the Utility of Electrocardiogram. A A Case Rep 2017; 9: 349-52.
6. Marks PW. Hematologic manifestations of liver disease. Semin Hematol 2013; 50: 216-21.
7. Shah NL, Intagliata NM, Northup PG, Argo CK, Caldwell SH. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol 2014; 11: 675-82.
8. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008; 48: 1000-7.
9. Bennani-Baiti N, Daw HA. Primary hyperfibrinolysis in liver disease: a critical review. Clin Adv Hematol Oncol 2011; 9: 250-2.
10. Senzolo M, Rodriguez-Castro KI, Rossetto V, Radu C, Gavasso S, Carraro P, Zerbinati P, Sartori MT, Simioni P. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 10: 1823-9.
11. Pugh Rn Fau - Murray-Lyon IM, Murray-Lyon Im Fau - Dawson JL, Dawson Jl Fau - Pietroni MC, Pietroni Mc Fau - Williams R, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-49.
12. Imura S, Shimada M, Utsunomiya T. Recent advances in estimating hepatic functional reserve in patients with chronic liver damage. Hepatol Res 2015; 45: 10-9.
13. Konstantinides Sv Fau - Meyer G, Meyer G Fau - Becattini C, Becattini C Fau - Bueno H, Bueno H Fau - Geersing G-J, Geersing Gj Fau - Harjola V-P, Harjola Vp Fau - Huisman MV, Huisman Mv Fau - Humbert M, Humbert M Fau - Jennings CS, Jennings Cs Fau - Jimenez D, Jimenez D Fau - Kucher N, Kucher N Fau - Lang IM, Lang Im Fau - Lankeit M, Lankeit M Fau - Lorusso R, Lorusso R Fau - Mazzolai L, Mazzolai L Fau - Meneveau N, Meneveau N Fau - Ni Ainle F, Ni Ainle F Fau - Prandoni P, Prandoni P Fau - Pruszczyk P, Pruszczyk P Fau - Righini M, Righini M Fau - Torbicki A, Torbicki A Fau - Van Belle E, Van Belle E Fau - Zamorano JL, Zamorano JL. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543-603.
14. Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol 2017; 98: 393-97.
15. Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci 2016; 61: 1721-27.
16. Kubitza D, Roth A Fau - Becka M, Becka M Fau - Alatrach A, Alatrach A Fau - Halabi A, Halabi A Fau - Hinrichsen H, Hinrichsen H Fau - Mueck W, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013; 76: 89-98.
17. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013; 52: 243-54.